Malaysia
Search
Sign In
Ophthalmology
Top Medical News
The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.
_1_2_Square.png)
Researchers from the Chinese University of Hong Kong (CUHK) have conducted the world’s first study to show that nightly use of low-concentration (0.05 percent) atropine eye drops may reduce the incidence of myopia in high-risk children.
In the treatment of patients with open-angle glaucoma (OAG), gel stent is noninferior to trabeculectomy in terms of reducing intraocular pressure (IOP) by at least 20 percent, according to a study. Trabeculectomy helps reduce IOP to a greater extent, whereas gel stent leads to fewer adverse events (AEs).
The novel NOV03 ophthalmic drop consisting of perfluorohexyloctane appears to help reduce both signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD), as shown in the results of the phase III MOJAVE study.
Myopia and primary open-angle glaucoma (POAG) share a strong bidirectional, genetic, causal relationship, which is primarily driven by intraocular pressure (IOP), suggest the results of a study.
Use of ranibizumab and lower-dose bevacizumab results in a higher rate of retreatment as compared with higher-dose bevacizumab use in patients with retinopathy of prematurity (ROP) initially treated with antivascular endothelial growth factors (anti-VEGFs), a study has shown.
New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Special Reports
A new algorithm objectively determines when intraocular lens implant (IOL) surgery should be performed, regardless of how the opacity looks to the surgeon.
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.